Table 2.
Comparison of investigations before and following Pioglitazone treatment.
| Investigations | Before treatment | At 12 month treatment | At 24 month treatment | Reference range |
|---|---|---|---|---|
| Weight (kg) | 49.0 | 48.6 | 50.5 | |
| Diabetes profile | ||||
| HBA1c (mmol/mol) | 61 | 42 | 31 | 20 - 40 |
| Glucose (mmol/L) | 12.0 | 4.0 | 3.7 | < 6.1 |
| Insulin (pmol/L) | 405 | ND* | ND* | 10 -60 |
| Liver enzymes | ||||
| ALT(IU/L) | 64 | 35 | 33 | < 30 |
| GGT(IU/L) | 34 | 16 | 15 | < 35 |
| Hormonal profile | ||||
| Free Testosterone (pmol/L) | 198 | 84 | ND* | < 50 |
| SHBG(nmol/L) | 16 | 14 | ND* | 20 - 90 |
| Free Androgen Index | 450 | 214 | ND* | < 80 |
| FSH (IU/L)# | 8.8 | 4.5 | 7.1 | 3 - 25 |
| LH (IU/L)# | 14.8 | 4.3 | 5.1 | 2.0 - 25 |
| Lipid profile | ||||
| TG (mmol/L) | 13.2 | 2.4 | 1.6 | < 1.7 |
| HDL (mmol/L) | 0.4 | 0.6 | 0.7 | > 1.0 |
| Total Cholesterol (mmol/L) | 4.7 | 3 | 3.8 | < 5.1 |
| LDL(mmol/L) | 2 | 1.3 | 2.4 | < 3.4 |
ND*: not done; # FSH: Follicle stimulating hormone; LH: Luteinizing hormone; LDL: Low density lipids
HDL: High density Lipids; TG: Triglyceride